ANTINEOPLASTIC AND OTHER HAZARDOUS DRUGS: RISK POTENTIAL AND EXPOSURE – LESS IS MORE!
NP-019
DEVELOPMENT OF A CONVERSION FACTOR BETWEEN DEFINED DAILY DOSES OF ADULTS AND NEONATES
NP-018
BUILDING CAPACITY WITHIN A HEPATITIS C TREATMENT MODEL. THE VALIDATION PROCESS FOR A HEPATITIS C PRE-TREATMENT PHARMACIST ASSESSMENT COMPLEX INTERVENTION TOOLKIT
NP-017
RISK ASSESSMENT OF OCCUPATIONAL EXPOSURE TO CYTOTOXIC DRUGS IN AN OUTPATIENT HOSPITAL PHARMACY
NP-016
EPIDEMIOLOGY AND RESISTANCE MAP TO AID ANTIBIOTIC GUIDELINE DEVELOPMENT SINGLE CENTRE RETROSPECTIVE STUDY FROM AN EMERGENCY DEPARTMENT
NP-015
QUALITY ASSESSMENT OF 3D PRINTED SILDENAFIL AND FUROSEMIDE TABLETS FOR THE PAEDIATRIC POPULATION USING AN INNOVATIVE EXTRUSIONBASED TECHNIQUE
NP-014
MEDICINE BOXES FOR DISTRIBUTION OF PAID PHARMACEUTICALS TO OUTPATIENTS IN THE FUTURE (submitted in 2019)
NP-013
THE NEOCHECK PROJECT: DEVELOPMENT OF A PRESCRIPTION-SCREENING TOOL SPECIFIC TO NEONATOLOGY (submitted in 2019)
NP-012
COST EFFECTIVENESS ANALYSIS AND INDIRECT COMPARISON CAN SUPPORT THE PRICE’ DEFINITION OF A DRUG? THE CASE OF ENCORAFENIB AND BINIMETINIB IN METASTATIC MELANOMA, THE PHARMACIST’POINT OF VIEW (submitted in 2019)
NP-011
MEDICATION RECONCILIATION IN AN EMERGENCY DEPARTMENT – PROCESS ASSESSMENT FOR A MORE EFFICIENT SERVICE (submitted in 2019)
NP-010
CLINICAL AND PHARMACOKINETIC RESULTS AFTER THE SWITCH TO INFLIXIMAB BIOSIMILAR IN INFLAMMATORY BOWEL DISEASE: 2 YEARS OF REAL-LIFE EXPERIENCE (submitted in 2019)
NP-009
THE IMPACT OF TNFa INHIBITORS ON GLUCOCORTICOIDS USE AMONG PATIENTS WITH ARTHRITIDES (submitted in 2019)
NP-008
MONITORING OF PRESCRIPTIONS ON PROPHYLAXIS OF VENOUS THROMBOEMBOLISM (VTE) IN MEDICAL PATIENTS IN BEATRIZ ÂNGELO HOSPITAL (submitted in 2019)
NP-007
A MIXED METHODS EVALUATION OF THE CROSS-SECTOR PHARMACIST VOCATIONAL TRAINING FOUNDATION PROGRAMME: IS THE TRAINING PROGRAMME FIT FOR PURPOSE? (submitted in 2019)
NP-006
A PAIR OF PHARMACY TECHNICIAN / NURSE TO TRAIN ON THE ANTI-RETURN VALVES (submitted in 2019)
